Company news

Cullinan Therapeutics, Inc. news in 2021

Cullinan Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

December 15, 2021

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

December 12, 2021

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results

November 8, 2021

Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer

October 17, 2021

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 9, 2021

Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

June 28, 2021

Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML

June 6, 2021

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

June 3, 2021

Cullinan Oncology Announces Management Transition

May 20, 2021

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

May 18, 2021

Cullinan Oncology Reports First Quarter 2021 Financial Results

May 13, 2021

Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights

March 29, 2021

Cullinan Management, Inc. Announces Business Update

February 21, 2021

Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 11, 2021

Cullinan Management Announces Pricing of Upsized Initial Public Offering

January 6, 2021

Decks in 2021